Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus PROCALAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus PROCALAMINE.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs PROCALAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution